B+
Bull case
30%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
CCCC
C4 TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$3.10
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.70
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+59.3
Score
AI commentary
Lean monitoring view. Recent primary-source news flow is constructive, especially the April 9, 2026 Roche collaboration and March 25, 2026 first-patient dosing in the elranatamab combination study, but this T+3 earnings follow-up did not uncover a company Q1 2026 earnings release, 8-K results filing, or 10-Q as of May 8, 2026, so post-print surprise, estimate revision, and target-change evidence remain unavailable. That keeps the thesis close to the deterministic prior: thesis_change_score improved to 0.685 and expected returns turned modestly positive, but evidence_quality_score is still only 0.54 and uncertainty remains elevated at 0.588. With thin coverage and no fresh quarterly filing, the setup stays neutral-to-watch rather than upgraded.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-15catalystMid-2026 additional cemsidomide Phase 1 analysisHigh impact
Management said it plans to present further analysis from the completed Phase 1 cemsidomide plus dexamethasone study in mid-2026, which remains the nearest efficacy and safety checkpoint for the lead multiple myeloma program and the clearest near-term test of whether the differentiated profile holds as development moves later stage [#10-K-2026-02-26] [#EX-99.1-2026-02-26].
2026-09-30eventElranatamab combination progress after first-patient dosingHigh impact
C4T announced first-patient dosing in the Phase 1b cemsidomide plus elranatamab study on March 25, 2026, and had guided to provide incremental progress through 2026. Clean dose-escalation and enrollment progress would help support the earlier-line myeloma strategy, but this remains an early execution checkpoint rather than a de-risked efficacy readout [#PR-2026-03-25] [#EX-99.1-2026-02-26].
2026-12-31catalystRoche degrader-antibody conjugate collaboration executionHigh impact
The April 9, 2026 Roche agreement adds a $20 million upfront payment plus large downstream milestone optionality, giving C4T a non-cemsidomide value lever and some funding support. The stock is unlikely to capitalize much of that headline value until investors see concrete research-stage progress or clearer cash-runway benefit from the collaboration economics [#8-K-2026-04-09].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology